SURF-201 met its primary endpoints in a phase 2 trial investigating the therapy in the treatment of post-cataract surgery pain and inflammation, according to a press release from Surface Ophthalmics.
In a trial of 91 patients, SURF-201 (betamethasone 0.2%) demonstrated complete clearance of anterior chamber cells, a marker for inflammation, at day 8 and day 15 (P = .01 and P = .001, respectively). For the secondary endpoint, almost 90% of patients were pain-free at day 15. Further, the treatment was safe and well-tolerated, and IOP did not increase more (Read more...)
Uncategorized